Neurology
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Correction (v69,p1889)
Right arrow Correspondence:
Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when Correspondence are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Russell, M. W.
Right arrow Articles by Menzin, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Russell, M. W.
Right arrow Articles by Menzin, J.
Related Collections
Right arrow All Health Services Research
Right arrow Cost effectiveness/economic
Right arrow Prognosis
Right arrow All Cerebrovascular disease/Stroke
Right arrow Intracerebral hemorrhage
NEUROLOGY 2006;67:1279-1281
© 2006 American Academy of Neurology
Brief Communications

Predictors of hospital length of stay and cost in patients with intracerebral hemorrhage

M. W. Russell, MAPE, A. V. Joshi, PhD, P. J. Neumann, ScD, L. Boulanger, MA, MBA and J. Menzin, PhD

From Boston Health Economics, Waltham, MA (M.W.R., L.B., J.M.); Novo Nordisk Inc., Princeton, NJ (A.V.J.); and Harvard School of Public Health, Boston, MA (P.J.N.).

Address correspondence and reprint requests to Mason W. Russell, Vice President, Research, Boston Health Economics, Inc., 20 Fox Rd., Waltham, MA 02451; e-mail: mrussell{at}bhei.com

We used the 2002 Healthcare Cost and Utilization Project Nationwide Inpatient Sample to assess hospital length of stay (LOS) and cost among adults with a principal diagnosis of intracerebral hemorrhage (n = 13,239). Sixty-nine percent of patients were aged ≥65 years, and 31% died during hospitalization. Mean LOS (cost) was 7.7 days ($15,256) (survivors: 9.6 days, $17,442). Patient, hospital, and payer characteristics accounted for 69.1% of variation in cost per discharge.

Disclosure: Funding for this study was provided by Novo Nordisk Inc., Princeton, NJ. With the exception of Dr. Joshi (a current employee of the sponsor who participated in research design, interpretation of findings, and manuscript preparation/review), the sponsor played no role in the design or conduct of the study. Dr. Joshi owns stock options in the sponsor. The employer of Mr. Russell, Mr. Boulanger, and Dr. Menzin received funding from the study sponsor in excess of $10,000 for other research not reported in this study. Dr. Neumann received honoraria from the study’s sponsor for participation in academic advisory boards.

Preliminary findings were presented at the 130th Annual Meeting of the American Neurologic Association, September 2005.

Received December 7, 2005. Accepted in final form June 6, 2006.




This article has been cited by other articles:


Home page
 StrokeHome page
S. R. Earnshaw, A. V. Joshi, M. R. Wilson, and J. Rosand
Cost-Effectiveness of Recombinant Activated Factor VII in the Treatment of Intracerebral Hemorrhage
Stroke, November 1, 2006; 37(11): 2751 - 2758.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2006 by AAN Enterprises, Inc.